Vertex Pharmaceuticals Inc (VRTX)
397.48
-0.22
(-0.06%)
USD |
NASDAQ |
Apr 26, 16:00
397.43
-0.05
(-0.01%)
After-Hours: 20:00
Vertex Pharmaceuticals Enterprise Value: 91.45B for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 91.45B |
| April 25, 2024 | 91.51B |
| April 24, 2024 | 92.30B |
| April 23, 2024 | 93.37B |
| April 22, 2024 | 92.08B |
| April 19, 2024 | 90.63B |
| April 18, 2024 | 90.42B |
| April 17, 2024 | 90.32B |
| April 16, 2024 | 90.60B |
| April 15, 2024 | 91.42B |
| April 12, 2024 | 91.21B |
| April 11, 2024 | 92.16B |
| April 10, 2024 | 91.48B |
| April 09, 2024 | 93.26B |
| April 08, 2024 | 93.19B |
| April 05, 2024 | 93.83B |
| April 04, 2024 | 93.14B |
| April 03, 2024 | 94.38B |
| April 02, 2024 | 94.54B |
| April 01, 2024 | 97.39B |
| March 28, 2024 | 96.76B |
| March 27, 2024 | 96.58B |
| March 26, 2024 | 96.87B |
| March 25, 2024 | 96.25B |
| March 22, 2024 | 96.15B |
| Date | Value |
|---|---|
| March 21, 2024 | 96.16B |
| March 20, 2024 | 95.23B |
| March 19, 2024 | 96.03B |
| March 18, 2024 | 95.04B |
| March 15, 2024 | 94.09B |
| March 14, 2024 | 94.37B |
| March 13, 2024 | 95.51B |
| March 12, 2024 | 95.32B |
| March 11, 2024 | 95.84B |
| March 08, 2024 | 95.62B |
| March 07, 2024 | 94.83B |
| March 06, 2024 | 95.17B |
| March 05, 2024 | 96.09B |
| March 04, 2024 | 98.31B |
| March 01, 2024 | 100.57B |
| February 29, 2024 | 97.46B |
| February 28, 2024 | 99.07B |
| February 27, 2024 | 100.09B |
| February 26, 2024 | 100.75B |
| February 23, 2024 | 99.88B |
| February 22, 2024 | 99.02B |
| February 21, 2024 | 97.18B |
| February 20, 2024 | 97.44B |
| February 16, 2024 | 97.84B |
| February 15, 2024 | 98.90B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.39B
Minimum
Oct 05 2021
103.73B
Maximum
Jan 30 2024
60.97B
Average
60.42B
Median
Apr 04 2022
Enterprise Value Benchmarks
| Amgen Inc | 198.36B |
| Eli Lilly and Co | 719.79B |
| Regeneron Pharmaceuticals Inc | 88.08B |
| Alpine Immune Sciences Inc | 3.904B |
| Moderna Inc | 32.74B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 968.80M |
| Revenue (Quarterly) | 2.518B |
| Total Expenses (Quarterly) | 1.562B |
| EPS Diluted (Quarterly) | 3.71 |
| Gross Profit Margin (Quarterly) | 85.38% |
| Profit Margin (Quarterly) | 38.48% |
| Earnings Yield | 3.49% |
| Operating Earnings Yield | 4.16% |
| Normalized Earnings Yield | 3.858 |